



CLEAR DIRECTION for Rapid Diagnosis of Pneumonia in Hospitalized Patients

The only FDA-cleared Pneumonia panel that detects *Pneumocystis jirovecii*.

Specimen Types:

- Endotracheal Aspirate
- Bronchoalveolar Lavage (including mini-BAL)

Comprehensive Testing Panel

FDA-cleared Unyvero uniquely and accurately detects the most clinically relevant pathogens and antibiotic resistance markers associated with pneumonia.

BACTERIA		RESISTANCE	GENES	
<i>Acinetobacter</i> spp.	<i>Moraxella catarrhalis</i>	Carbapenems	<i>kpc</i>	<i>oxa-48</i>
<i>Chlamydia pneumoniae</i>	<i>Morganella morganii</i>		<i>ndm</i>	<i>oxa-58</i>
<i>Citrobacter freundii</i>	<i>Mycoplasma pneumoniae</i>		<i>oxa-23</i>	<i>vim</i>
<i>Enterobacter cloacae</i> complex	<i>Proteus</i> spp.		<i>oxa-24</i>	
<i>Escherichia coli</i>	<i>Pseudomonas aeruginosa</i>	3rd Generation Cephalosporins	<i>ctx-M</i>	
<i>Haemophilus influenzae</i>	<i>Serratia marcescens</i>			
<i>Klebsiella oxytoca</i>	<i>Staphylococcus aureus</i>	Oxacillin/Cefoxitin	<i>mecA</i>	
<i>Klebsiella pneumoniae</i>	<i>Stenotrophomonas maltophilia</i>	Penicillin	<i>tem</i>	
<i>Klebsiella variicola</i>	<i>Streptococcus pneumoniae</i>			
<i>Legionella pneumophila</i>				
FUNGI				
<i>Pneumocystis jirovecii</i> *				



* included on the Unyvero LRT BAL panel.

- **Rapid, sample-to-answer**
- **Direct from specimen**
- **Simple and clear qualitative results based on quantitative algorithms**
- **Critical information for life-saving treatment decisions**

One patient sample. Comprehensive results. **Unyvero points the way.**

CLEAR DIRECTION for hospitalized pneumonia patients

Pneumonia can be fatal

Clinical outcomes are highly dependent upon timely and appropriate therapy. Unfortunately, standard of care microbiology has a number of limitations, including¹:

- Takes several days to get results
- Fails to determine a causative agent in >50% of pneumonia patients
- Affected by sample transport time
- Exposure to unnecessary broad-spectrum antibiotics

Unyvero is Changing the Status Quo

Greater Diagnostic Accuracy Can Save Lives


Unyvero LRT has demonstrated correct identification of key pathogens that are often missed by culture, without relying on the growth of viable organisms.

Unyvero LRT identified *Acinetobacter* cases that were initially culture-negative but all had a subsequent culture that grew *Acinetobacter*. **All patients with initial negative culture for *Acinetobacter* died².**

Unyvero Supports Antibiotic Stewardship

Potential Impact on Antibiotic Therapy³

- Unyvero panel favors narrowing over expanding antibiotic coverage nearly 2-fold (29% vs. 15%).
- Unyvero could potentially optimize antibiotic therapy in >50% of cases.



Get Clear Direction

Unyvero LRT quickly delivers actionable answers to reduce the time to appropriate therapy and drive optimal, cost-effective care for hospitalized pneumonia patients. For clear, comprehensive, and reliable results to advance antimicrobial stewardship initiatives, **Unyvero points the way.**

Request an evaluation today: curetisusa.com | info_us@curetis.com



References:
1. Messika J, Stoclin A, Bouvard E, et al. The Challenging Diagnosis of Non-Community-Acquired Pneumonia in Non-Mechanically Ventilated Subjects: Value of Microbiological Investigation. *Respir Care*. 2016;61(2):225234. doi:10.4187/respcare.04143
2. Pickens C, et al. Rapid diagnostic testing of bronchoalveolar lavage to detect non-fermenting gram-negative bacteria and antibiotic resistance genes. Poster presented at: American Thoracic Society; 2018 May 18-23; San Diego, CA.
3. Mopuru H, et al. Evaluation of a rapid highly multiplexed molecular diagnostic lower respiratory tract panel for clinical impact and antibiotic stewardship. Poster presented at: American Society for Microbiology Microbe; 2018 Jun 6-11; Atlanta, GA.